BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Ye XG, Su QM. Effects of entecavir and lamivudine for hepatitis B decompensated cirrhosis: Meta-analysis. World J Gastroenterol 2013; 19(39): 6665-6678 [PMID: 24151397 DOI: 10.3748/wjg.v19.i39.6665]
URL: https://www.wjgnet.com/1007-9327/full/v19/i39/6665.htm
Number Citing Articles
1
Pietro Lampertico, Kosh Agarwal, Thomas Berg, Maria Buti, Harry L.A. Janssen, George Papatheodoridis, Fabien Zoulim, Frank Tacke. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. Journal of Hepatology 2017; 67(2) doi: 10.1016/j.jhep.2017.03.021
2
Gaeun Kim, Soon Koo Baik. Overview and recent trends of systematic reviews and meta-analyses in hepatology. Clinical and Molecular Hepatology 2014; 20(2) doi: 10.3350/cmh.2014.20.2.137
3
JinSong Geng, HaiNi Bao, YaLan Chen, LiLi Shi, Jing Geng, Qing Wang, Hao Yu. Nucleos(t)ide analogues for the treatment of chronic hepatitis B: a systematic review with network meta-analysis. Expert Review of Anti-infective Therapy 2020; 18(8) doi: 10.1080/14787210.2020.1760843
4
Yiqi Yu, Jingwen Ai, Wenhong Zhang. Current clinical evidence for nucleos(t)ide analogues in patients with HBV-related hepatocellular carcinoma. Expert Review of Gastroenterology & Hepatology 2017; 11(10) doi: 10.1080/17474124.2017.1343665
5
Bipindra Pandey, Rishiram Baral, Atisammodavardhana Kaundinnyayana, Sushil Panta. Promising hepatoprotective agents from the natural sources: a study of scientific evidence. Egyptian Liver Journal 2023; 13(1) doi: 10.1186/s43066-023-00248-w
6
HAO ZHANG, YUCHEN ZHOU, GUOSHENG YUAN, GUANGYAO ZHOU, DINGHUA YANG, YUANPING ZHOU. Antiviral therapy improves the survival rate and decreases recurrences and fatalities in liver cancer patients following curative resection: A meta-analysis. Molecular and Clinical Oncology 2015; 3(6) doi: 10.3892/mco.2015.614
7
Evangelos Cholongitas, Konstantinos Tziomalos, Chrysoula Pipili. Management of patients with hepatitis B in special populations. World Journal of Gastroenterology 2015; 21(6): 1738-1748 doi: 10.3748/wjg.v21.i6.1738
8
Christoph Höner zu Siederdissen, Markus Cornberg. Management of HBV and HBV/HDV-Associated Liver Cirrhosis. Visceral Medicine 2016; 32(2) doi: 10.1159/000445518
9
Chih-Yang Lin, Wei-Chih Sun, Chia-Ming Lu, Wen-Chi Chen, Feng-Woei Tsay, Tzun-Jiun Tsai, Feng-Yu Kuo, Wei-Lun Tsai. Entecavir vs. tenofovir disoproxil fumarate in the treatment of chronic hepatitis B patients with severe acute exacerbation. European Journal of Gastroenterology & Hepatology 2024; 36(9) doi: 10.1097/MEG.0000000000002709
10
Teng-Yu Lee, Chi-Yi Chen, Hsueh-Chou Lia, Yu-Chung Hsu, Sheng-Shun Yang. The Ultra-Short Virological Dynamics in Response to Entecavir or Lamivudine during Chronic Hepatitis B with Spontaneous Severe Acute Exacerbation. Antiviral Therapy 2018; 23(1) doi: 10.3851/IMP3183
11
Daniel Shouval. The pros and cons of lamivudine vs. entecavir in decompensated or severe acute exacerbation of chronic hepatitis B. Journal of Hepatology 2014; 60(6) doi: 10.1016/j.jhep.2014.03.004
12
Yuanyuan Kong, Tingting Lv, Min Li, Lianghui Zhao, Tongtong Meng, Shanshan Wu, Wei Wei, Qian Zhang, Sha Chen, Hong You, Sabela Lens, Hitoshi Yoshiji, Sven Francque, Emmanouil Tsochatzis, Shiv K. Sarin, Mattias Mandorfer, Jidong Jia. Systematic review and meta-analysis: impact of anti-viral therapy on portal hypertensive complications in HBV patients with advanced chronic liver disease. Hepatology International 2022; 16(5) doi: 10.1007/s12072-022-10369-w
13
Lai Wei, Jia-Horng Kao. Benefits of long-term therapy with nucleos(t)ide analogues in treatment-naïve patients with chronic hepatitis B. Current Medical Research and Opinion 2017; 33(3) doi: 10.1080/03007995.2016.1264932
14
Chrysoula Pipili, Evangelos Cholongitas. Μanagement of patients with hepatitis B and C before and after liver and kidney transplantation. World Journal of Hepatology 2014; 6(5): 315-325 doi: 10.4254/wjh.v6.i5.315
15
Hiroshi KAKUTO, Genki SHIMIZU, Denichiro YAMAOKA. <b>A Case of Refractory Ascites with Liver Cirrhosis Successfully Treated by the Combination of Inchinkoto and Goreisan (Inchinkoto-Go-Goreisan)</b>. Kampo Medicine 2015; 66(4) doi: 10.3937/kampomed.66.337
16
Wenjun Liu, Renjie Liu, Peng Li, Ruyi Xia, Zhuoru Zou, Lei Zhang, Mingwang Shen, Guihua Zhuang. Modeling hepatitis B-related deaths in China to achieve the WHO's impact target. Infectious Disease Modelling 2025; 10(2) doi: 10.1016/j.idm.2025.02.010
17
Norah A. Terrault, Natalie H. Bzowej, Kyong‐Mi Chang, Jessica P. Hwang, Maureen M. Jonas, M. Hassan Murad. AASLD guidelines for treatment of chronic hepatitis B. Hepatology 2016; 63(1) doi: 10.1002/hep.28156
18
Andreas Krause, Uwe Haberkorn, Walter Mier. Strategies for the treatment of HBV/HDV. European Journal of Pharmacology 2018; 833 doi: 10.1016/j.ejphar.2018.06.030
19
Zhuo-Lun Song, Yu-Jun Cui, Wei-Ping Zheng, Da-Hong Teng, Hong Zheng. Application of nucleoside analogues to liver transplant recipients with hepatitis B. World Journal of Gastroenterology 2015; 21(42): 12091-12100 doi: 10.3748/wjg.v21.i42.12091
20
Wei-Lun Tsai, Wei-Chi Sun, Jin-Shiung Cheng. Chronic Hepatitis B with Spontaneous Severe Acute Exacerbation. International Journal of Molecular Sciences 2015; 16(12) doi: 10.3390/ijms161226087
21
Young-Cheol Ju, Dae-Won Jun, Jun Choi, Waqar Khalid Saeed, Hyo-Young Lee, Hyun-Woo Oh. Long term outcome of antiviral therapy in patients with hepatitis B associated decompensated cirrhosis. World Journal of Gastroenterology 2018; 24(40): 4606-4614 doi: 10.3748/wjg.v24.i40.4606
22
Wan Yue-Meng, Yu-Hua Li, Hua-Mei Wu, Jing Yang, Ying Xu, Li-Hong Yang, Jin-Hui Yang. Telbivudine versus lamivudine and entecavir for treatment-naïve decompensated hepatitis B virus-related cirrhosis. Clinical and Experimental Medicine 2017; 17(2) doi: 10.1007/s10238-016-0420-7
23
Li Xie, Juan Yin, Ruyi Xia, Guihua Zhuang. Cost‐effectiveness of antiviral treatment after resection in hepatitis B virus–related hepatocellular carcinoma patients with compensated cirrhosis. Hepatology 2018; 68(4) doi: 10.1002/hep.29922
24
Norah A. Terrault, Anna S.F. Lok, Brian J. McMahon, Kyong‐Mi Chang, Jessica P. Hwang, Maureen M. Jonas, Robert S. Brown, Natalie H. Bzowej, John B. Wong. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 2018; 67(4) doi: 10.1002/hep.29800
25
Lemonica Koumbi. Current and future antiviral drug therapies of hepatitis B chronic infection. World Journal of Hepatology 2015; 7(8): 1030-1040 doi: 10.4254/wjh.v7.i8.1030
26
Xiaoli Fan, Liyu Chen, Jingyu Yang, Ping Feng. Entecavir-Associated Thrombocytopenia in a Decompensated Cirrhotic Patient. Medicine 2016; 95(12) doi: 10.1097/MD.0000000000003103
27
F.Y. Wang, B. Li, Y. Li, H. Liu, W.D. Qu, H.W. Xu, J.N. Qi, C.Y. Qin. Entecavir for Patients with Hepatitis B Decompensated Cirrhosis in China: a meta-analysis. Scientific Reports 2016; 6(1) doi: 10.1038/srep32722
28
James Fung, Ching-Lung Lai, Man-Fung Yuen. Management of chronic hepatitis B in severe liver disease. World Journal of Gastroenterology 2014; 20(43): 16053-16061 doi: 10.3748/wjg.v20.i43.16053
29
Tsung-Hsing Hung, Chih-Chun Tsai, Hsing-Feng Lee. Population-based study of Entecavir and long-term mortality in chronic hepatitis B–related decompensated liver cirrhosis. Clinics and Research in Hepatology and Gastroenterology 2019; 43(6) doi: 10.1016/j.clinre.2019.02.010
30
You-Wen Tan, Yun Ye, Guo-Hong Ge, Wei Zhao, Jian-He Gan, Yun Zhao, Zhi-Lin Niu, Dong-Jun Zhang, Li Chen, Xue-Jun Yu, Li-Jun Yang. Natural YMDD-motif mutants affect clinical course of lamivudine in chronic hepatitis B. World Journal of Gastroenterology 2015; 21(7): 2089-2095 doi: 10.3748/wjg.v21.i7.2089
31
Anil Arora, Anil C. Anand, Ashish Kumar, Shivaram P. Singh, Rakesh Aggarwal, Radha K. Dhiman, Shyam Aggarwal, Seema Alam, Pradeep Bhaumik, Vinod K. Dixit, Ashish Goel, Bhabadev Goswami, Ashok Kumar, Manoj Kumar, Kaushal Madan, Natarajan Murugan, Aabha Nagral, Amarender S. Puri, Padaki N. Rao, Neeraj Saraf, Vivek A. Saraswat, Sanjeev Sehgal, Praveen Sharma, Koticherry T. Shenoy, Manav Wadhawan. INASL Guidelines on Management of Hepatitis B Virus Infection in Patients receiving Chemotherapy, Biologicals, Immunosupressants, or Corticosteroids. Journal of Clinical and Experimental Hepatology 2018; 8(4) doi: 10.1016/j.jceh.2018.06.010